Prevalence of Granulomas in Patients With Primary Immunodeficiency Disorders, United States

Data From National Health Care Claims and the US Immunodeficiency Network Registry

Jessica Leung*, Kathleen E. Sullivan, Ludmila Perelygina, Joseph P. Icenogle, Ramsay L Fuleihan, Tatiana M. Lanzieri

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Purpose: Granulomas are a potentially severe condition that can last for several years in persons with primary immunodeficiency disorders (PIDD). We assessed the prevalence of granulomas in patients with PIDD. Methods: We used the Truven Health MarketScan® 2005–2015 Commercial Claims and Encounters and 2006–2015 Medicaid databases and the US Immunodeficiency Network (USIDNET) PIDD registry (a program of the Immune Deficiency Foundation). Our study population consisted of persons age < 65 years with PIDD, defined as persons with ≥ 2 claims with a diagnostic code for PIDD in MarketScan databases, or patients enrolled in USIDNET. Granulomas were identified using diagnostic codes in MarketScan or provider report in USIDNET. We calculated annual prevalence of PIDD and of granulomas among PIDD patients. Results: We identified 247,474 and 40,395 persons with PIDD among commercially and Medicaid-insured persons, respectively. PIDD prevalence was 6.0/10,000 in 2005 and 11.7/10,000 in 2015 among commercially insured persons and 5.5/10,000 in 2006 and 9.6/10,000 in 2015 among Medicaid-insured persons. The prevalence of granulomas among PIDD patients was 1.2 and 1.5% among commercially and Medicaid-insured persons, respectively. In USIDNET, prevalence of granulomas was 4.4% (177/4021). The proportion with granulomas was similar across age groups in MarketScan, but varied from 2 to 9% in USIDNET. The reported prevalence of granulomas differed depending on PIDD condition: 1–2% in the MarketScan data and 0–13% in USIDNET. Conclusion: Granuloma prevalence in PIDD patients was 1–4%. Our study provides an estimate of the proportion of PIDD patients and suggests that granulomas are an uncommon occurrence among patients with PIDD.

Original languageEnglish (US)
Pages (from-to)717-726
Number of pages10
JournalJournal of Clinical Immunology
Volume38
Issue number6
DOIs
StatePublished - Aug 1 2018

Fingerprint

Granuloma
Registries
Delivery of Health Care
Medicaid
Databases
Age Groups
Health

Keywords

  • Granulomas
  • MarketScan
  • PIDD
  • Primary immunodeficiency disorders
  • USIDNET registry
  • United States

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{8c65c766972e410f95a94abf4d52c844,
title = "Prevalence of Granulomas in Patients With Primary Immunodeficiency Disorders, United States: Data From National Health Care Claims and the US Immunodeficiency Network Registry",
abstract = "Purpose: Granulomas are a potentially severe condition that can last for several years in persons with primary immunodeficiency disorders (PIDD). We assessed the prevalence of granulomas in patients with PIDD. Methods: We used the Truven Health MarketScan{\circledR} 2005–2015 Commercial Claims and Encounters and 2006–2015 Medicaid databases and the US Immunodeficiency Network (USIDNET) PIDD registry (a program of the Immune Deficiency Foundation). Our study population consisted of persons age < 65 years with PIDD, defined as persons with ≥ 2 claims with a diagnostic code for PIDD in MarketScan databases, or patients enrolled in USIDNET. Granulomas were identified using diagnostic codes in MarketScan or provider report in USIDNET. We calculated annual prevalence of PIDD and of granulomas among PIDD patients. Results: We identified 247,474 and 40,395 persons with PIDD among commercially and Medicaid-insured persons, respectively. PIDD prevalence was 6.0/10,000 in 2005 and 11.7/10,000 in 2015 among commercially insured persons and 5.5/10,000 in 2006 and 9.6/10,000 in 2015 among Medicaid-insured persons. The prevalence of granulomas among PIDD patients was 1.2 and 1.5{\%} among commercially and Medicaid-insured persons, respectively. In USIDNET, prevalence of granulomas was 4.4{\%} (177/4021). The proportion with granulomas was similar across age groups in MarketScan, but varied from 2 to 9{\%} in USIDNET. The reported prevalence of granulomas differed depending on PIDD condition: 1–2{\%} in the MarketScan data and 0–13{\%} in USIDNET. Conclusion: Granuloma prevalence in PIDD patients was 1–4{\%}. Our study provides an estimate of the proportion of PIDD patients and suggests that granulomas are an uncommon occurrence among patients with PIDD.",
keywords = "Granulomas, MarketScan, PIDD, Primary immunodeficiency disorders, USIDNET registry, United States",
author = "Jessica Leung and Sullivan, {Kathleen E.} and Ludmila Perelygina and Icenogle, {Joseph P.} and Fuleihan, {Ramsay L} and Lanzieri, {Tatiana M.}",
year = "2018",
month = "8",
day = "1",
doi = "10.1007/s10875-018-0534-7",
language = "English (US)",
volume = "38",
pages = "717--726",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "6",

}

Prevalence of Granulomas in Patients With Primary Immunodeficiency Disorders, United States : Data From National Health Care Claims and the US Immunodeficiency Network Registry. / Leung, Jessica; Sullivan, Kathleen E.; Perelygina, Ludmila; Icenogle, Joseph P.; Fuleihan, Ramsay L; Lanzieri, Tatiana M.

In: Journal of Clinical Immunology, Vol. 38, No. 6, 01.08.2018, p. 717-726.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prevalence of Granulomas in Patients With Primary Immunodeficiency Disorders, United States

T2 - Data From National Health Care Claims and the US Immunodeficiency Network Registry

AU - Leung, Jessica

AU - Sullivan, Kathleen E.

AU - Perelygina, Ludmila

AU - Icenogle, Joseph P.

AU - Fuleihan, Ramsay L

AU - Lanzieri, Tatiana M.

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Purpose: Granulomas are a potentially severe condition that can last for several years in persons with primary immunodeficiency disorders (PIDD). We assessed the prevalence of granulomas in patients with PIDD. Methods: We used the Truven Health MarketScan® 2005–2015 Commercial Claims and Encounters and 2006–2015 Medicaid databases and the US Immunodeficiency Network (USIDNET) PIDD registry (a program of the Immune Deficiency Foundation). Our study population consisted of persons age < 65 years with PIDD, defined as persons with ≥ 2 claims with a diagnostic code for PIDD in MarketScan databases, or patients enrolled in USIDNET. Granulomas were identified using diagnostic codes in MarketScan or provider report in USIDNET. We calculated annual prevalence of PIDD and of granulomas among PIDD patients. Results: We identified 247,474 and 40,395 persons with PIDD among commercially and Medicaid-insured persons, respectively. PIDD prevalence was 6.0/10,000 in 2005 and 11.7/10,000 in 2015 among commercially insured persons and 5.5/10,000 in 2006 and 9.6/10,000 in 2015 among Medicaid-insured persons. The prevalence of granulomas among PIDD patients was 1.2 and 1.5% among commercially and Medicaid-insured persons, respectively. In USIDNET, prevalence of granulomas was 4.4% (177/4021). The proportion with granulomas was similar across age groups in MarketScan, but varied from 2 to 9% in USIDNET. The reported prevalence of granulomas differed depending on PIDD condition: 1–2% in the MarketScan data and 0–13% in USIDNET. Conclusion: Granuloma prevalence in PIDD patients was 1–4%. Our study provides an estimate of the proportion of PIDD patients and suggests that granulomas are an uncommon occurrence among patients with PIDD.

AB - Purpose: Granulomas are a potentially severe condition that can last for several years in persons with primary immunodeficiency disorders (PIDD). We assessed the prevalence of granulomas in patients with PIDD. Methods: We used the Truven Health MarketScan® 2005–2015 Commercial Claims and Encounters and 2006–2015 Medicaid databases and the US Immunodeficiency Network (USIDNET) PIDD registry (a program of the Immune Deficiency Foundation). Our study population consisted of persons age < 65 years with PIDD, defined as persons with ≥ 2 claims with a diagnostic code for PIDD in MarketScan databases, or patients enrolled in USIDNET. Granulomas were identified using diagnostic codes in MarketScan or provider report in USIDNET. We calculated annual prevalence of PIDD and of granulomas among PIDD patients. Results: We identified 247,474 and 40,395 persons with PIDD among commercially and Medicaid-insured persons, respectively. PIDD prevalence was 6.0/10,000 in 2005 and 11.7/10,000 in 2015 among commercially insured persons and 5.5/10,000 in 2006 and 9.6/10,000 in 2015 among Medicaid-insured persons. The prevalence of granulomas among PIDD patients was 1.2 and 1.5% among commercially and Medicaid-insured persons, respectively. In USIDNET, prevalence of granulomas was 4.4% (177/4021). The proportion with granulomas was similar across age groups in MarketScan, but varied from 2 to 9% in USIDNET. The reported prevalence of granulomas differed depending on PIDD condition: 1–2% in the MarketScan data and 0–13% in USIDNET. Conclusion: Granuloma prevalence in PIDD patients was 1–4%. Our study provides an estimate of the proportion of PIDD patients and suggests that granulomas are an uncommon occurrence among patients with PIDD.

KW - Granulomas

KW - MarketScan

KW - PIDD

KW - Primary immunodeficiency disorders

KW - USIDNET registry

KW - United States

UR - http://www.scopus.com/inward/record.url?scp=85050614325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050614325&partnerID=8YFLogxK

U2 - 10.1007/s10875-018-0534-7

DO - 10.1007/s10875-018-0534-7

M3 - Article

VL - 38

SP - 717

EP - 726

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 6

ER -